Drugs / MODIMELANOTIDE
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01897519 | May 2013 → May 2014 | — | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT01777165 | Feb 2013 → Mar 2014 | acute kidney injury | AbbVie | Completed | Missed primary |
| Phase 2 | NCT01256372 | Oct 2010 → Jun 2011 | aortic aneurysm, kidney disorder | Action Pharma A/S | Completed | No outcome recorded |
| Phase 2 | NCT00903604 | May 2009 → Jun 2010 | aneurysm or dilatation of ascending aorta, cardiac valvular defect | Action Pharma A/S | Completed | No outcome recorded |
| Phase 2 | NCT00628264 | Mar 2008 → Jun 2009 | acute kidney injury, cardiac valvular defect, coronary artery intramyocardial course | Action Pharma A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MODIMELANOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545104 ↗ |
| Known as | ABT-719 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01897519 ↗ |
| Known as | AP214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00903604 ↗ |
| Known as | Modimelanotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545104 ↗ |
| Known as | ZP-1480 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545104 ↗ |
| Action | Activate | “Melanocortin receptor 3 agonist” CHEMBL3545104 ↗1“Melanocortin receptor 1 agonist” CHEMBL3545104 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3545104 ↗ |
| Target | MC1R | “Melanocortin receptor 1 agonist” CHEMBL3545104 ↗ |
| Target | MC3R | “Melanocortin receptor 3 agonist” CHEMBL3545104 ↗ |